Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer’s Disease (A4) Study – Supplementary Data

Deters, Kacie, Stanford University, https://orcid.org/0000-0002-3314-0566

Napolioni, Valerio, Stanford University

Sperling, Reisa, Brigham and Women’s Hospital, Massachusetts General Hospital

Kennedy, Gabriel, Stanford University

Greicius, Michael, Stanford University

Mayeux, Richard, Columbia University

Hohman, Timothy, Vanderbilt University

Mormino, Elizabeth, Stanford University

kdeters@stanford.edu

Published Apr 23, 2021 on Dryad. https://doi.org/10.5061/dryad.7h44j0zsh

Cite this dataset

Deters, Kacie et al. (2021). Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer’s Disease (A4) Study – Supplementary Data [Dataset]. Dryad. https://doi.org/10.5061/dryad.7h44j0zsh

Abstract

The goal of the manuscript was to examine whether amyloid PET in CN individuals that were screened for the Anti-Amyloid in Asymptomatic AD (A4) study differed across self-identified, non-Hispanic White and Black (NHW and NHB) groups. We examined 3685 NHW and 144 NHB that passed initial screening for the A4 study and underwent amyloid PET. The effect of race on amyloid PET was examined using logistic (dichotomous groups) and linear (continuous values) regression controlling for age, sex, and number of APOE ε4 and APOE ε2 alleles. Lifestyle factors and medical conditions were available for the majority of individuals that received an amyloid PET scan. Additional sensitivity analyses were run to examine potential effects between amyloid and lifestyle as well as self-reported medical conditions that differed by race. Reduced amyloid was observed in self-identified non-Hispanic Blacks that passed initial eligibility criteria for the A4 Study, but lifestyle and vascular factors did not impact this effect. This work stresses the importance of investigating AD biomarkers in ancestrally diverse samples as well as the need for careful consideration regarding study eligibility criteria in AD prevention trials.